(S (NP (NML (NN Machine) (NN learning)) (CC and) (NML (JJ deep) (NN learning))) (VP (VP (VBP have) (VP (VBN gained) (NP (NN popularity)))) (CC and) (VP (VBD achieved) (NP (JJ immense) (NN success)) (PP (IN in) (NP (NP (NN Drug) (NN discovery)) (PP (IN in) (NP (JJ recent) (NNS decades))))))) (. .))
(S (ADVP (RB Historically)) (, ,) (NP (NML (NML (NN machine) (NN learning)) (CC and) (NML (JJ deep) (NN learning))) (NNS models)) (VP (VBD were) (VP (VBN trained) (PP (IN on) (NP (CC either) (NP (JJ structural) (NNS data)) (CC or) (NP (NN chemical) (NNS properties)))) (PP (IN by) (NP (ADJP (JJ separated)) (NN model))))) (. .))
(S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP (PRP we)) (VP (VBD proposed) (NP (DT an) (NN architecture) (NN training)) (NP-TMP (ADVP (RB simultaneously)) (NP (DT both) (NN type)) (PP (IN of) (NP (NNS data))) (PP (IN in) (NP (NN order)))) (S (VP (TO to) (VP (VB improve) (NP (DT the) (JJ overall) (NN performance)))))) (. .))
(S (PP (VBN Given) (NP (NP (DT the) (JJ molecular) (NN structure)) (PP (IN in) (NP (NP (DT the) (NN form)) (PP (IN of) (NP (NP (NNP SMILES) (NN notation)) (CC and) (NP (PRP$ their) (NN label)))))))) (, ,) (NP (PRP we)) (VP (VBD generated) (NP (NP (DT the) (ADJP (NP (NN SMILES)) (HYPH -) (VBN based)) (NN feature) (NN matrix)) (CC and) (NP (JJ molecular) (NNS descriptors)))) (. .))
(S (NP (DT These) (NNS data)) (VP (VBD were) (VP (VBN trained) (PP (IN on) (NP (NP (DT a) (NML (JJ deep) (NN learning)) (NN model)) (SBAR (WHNP (WDT which)) (S (VP (VBD was) (ADVP (RB also)) (VP (VBN integrated) (PP (IN with) (NP (DT the) (NN Attention) (NN mechanism))) (S (VP (TO to) (VP (VB facilitate) (NP (NN training) (CC and) (NN interpreting))))))))))))) (. .))
(S (NP (NNS Experiments)) (VP (VBD showed) (SBAR (IN that) (S (NP (PRP$ our) (NN model)) (VP (MD could) (VP (VB raise) (NP (NP (DT the) (NN performance)) (PP (IN of) (NP (NP (NN prediction)) (VP (VBG comparing) (PP (IN to) (NP (DT the) (NN reference)))))))))))) (. .))
(S (PP (IN With) (NP (DT the) (JJ maximum) (NNP MCC) (NML (NML (CD 0.58)) (CC and) (NML (NNP AUC)) (NP (NP (CD 90) (NN %)) (PP (IN by) (NP (NP (NN cross-validation)) (PP (IN on) (NP (NNP EGFR) (NNS inhibitors))))))) (NN dataset))) (, ,) (NP (PRP$ our) (NN architecture)) (VP (VBD was) (VP (VBG outperforming) (NP (DT the) (NML (S (VP (VBG referring)))) (NN model)))) (. .))
(S (NP (PRP We)) (ADVP (RB also)) (ADVP (RB successfully)) (VP (VBN integrated) (NP (NN Attention) (NN mechanism)) (PP (IN into) (NP (NP (PRP$ our) (NN model)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD helped) (S (VP (TO to) (VP (VB interpret) (NP (NP (DT the) (NN contribution)) (PP (IN of) (NP (JJ chemical) (NNS structures)))))))))))) (PP (IN on) (NP (NN bioactivity)))) (. .))
